Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2020-01-03 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and plans for continued repurchases. The text explicitly mentions the repurchase of company shares, the use of company funds, and adherence to regulatory rules for share buybacks. There is no indication that this is a full financial report or an earnings release; rather, it is a progress update on the company's share buyback activity. Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on share repurchase progress, confirming it is not a full report but an announcement of ongoing transactions in own shares.
2020-01-03 Chinese
关于获得“Enarodustat”独家许可使用权的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acquisition of exclusive licensing rights for the drug 'Enarodustat' from Japan Tobacco Inc. It details the transaction overview, parties involved, terms of the agreement, payment milestones, risks, and board approval. The content focuses on a capital transaction involving intellectual property licensing and does not contain financial statements, earnings data, or regulatory certifications. It is not a full annual or interim report, nor an earnings release or management discussion. The document is a formal announcement of a capital/financing update related to licensing and investment activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (4694 characters) and detailed transaction description support this classification with high confidence.
2019-12-25 Chinese
第四届董事会第二十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the Shenzhen Xintai Pharmaceutical Co., Ltd. Fourth Board of Directors 27th meeting held on December 24, 2019. It includes nominations for the fifth board of directors, independent director candidates, remuneration proposals for independent directors, and authorization for signing agreements related to licensing. It also contains detailed biographies of the nominated directors. The content focuses on board and management changes, nominations, and related governance matters. There is no indication of financial statements, audit reports, earnings data, or regulatory certifications. The document is not a report publication announcement as it contains substantive content rather than just a notice. Therefore, the document fits best under the category of Board/Management Information (MANG).
2019-12-25 Chinese
独立董事候选人声明（ZHANG MENG）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate, Zhang Meng, for Shenzhen Xinlitai Pharmaceutical Co., Ltd. It contains detailed statements confirming compliance with various legal, regulatory, and stock exchange requirements for independent directors. The content focuses on qualifications, independence, and legal compliance of the director candidate rather than financial data, management changes, or meeting results. There is no indication of financial reporting, voting results, or management announcements. This type of document is typically related to board or management information, specifically announcements about board member candidates or changes. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a certification but a substantive declaration related to board membership.
2019-12-25 Chinese
独立董事候选人声明（刘来平）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It contains detailed statements confirming the candidate's qualifications, independence, and compliance with various regulatory requirements for serving as an independent director. There are no financial statements, earnings data, or management discussion of financial results. The document is not an announcement of a report but a standalone declaration related to board/management information, specifically concerning the appointment and qualifications of a board member. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (5155 characters) supports it being a full declaration rather than a brief announcement or certification.
2019-12-25 Chinese
独立董事提名人声明（三）
Board/Management Information Classification · 95% confidence The document is a public statement from the board of Shenzhen Xinlitai Pharmaceutical Co., Ltd. nominating an individual (ZHANG MENG) as an independent director candidate for the company's fifth board. It contains detailed declarations about the nominee's qualifications, compliance with various regulatory requirements, and independence criteria. There is no financial data, no discussion of financial results, no mention of annual or interim reports, earnings, or capital changes. The content is focused on board/management information specifically related to the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length (5223 characters) and detailed content support this classification with high confidence.
2019-12-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.